Kymera Therapeutics

Test Release PRN

*** This is a test sample for PRNewswire quarterly results release style. It will need to be removed before the site is set to live. *** DIVISIONR (valbenazine) Second Quarter Net Product Sales of $96.9 Million with Approximately 16,700 TRx DIVISION? (elagolix), the First FDA-Approved Oral